Umbilical Cord Blood Transplantation: Challenges and Future Directions

KAREN BALLEN

SUMMARY

Since the first successful allogeneic transplants performed in Seattle 50 years ago, the field of transplantation has evolved considerably, with improvements in human leukocyte antigen typing, patient selection, reduced intensity regimens, and graft-versus-host disease prophylaxis. A major breakthrough has been the availability of more donor options, first via the National Marrow Donor Program—Be the Match [Biol Blood Marrow Transplant 2008;14:2–7]. Then, in the 1990s, unrelated umbilical cord blood transplantation became available, first for children and then for adults [New Engl J Med 1996;35:157–166]. More recently mismatched unrelated transplants and haploidentical donor options became available [Blood 2011;118:282–288]. In 2017, there is a donor for almost every patient who needs a transplant. In this review, we will discuss the state of the science (and art) of cord blood transplant, focusing on successes, challenges, and future directions.

SIGNIFICANCE STATEMENT

From the first UCBT in 1988, the field of UCBT has evolved considerably. UCBT is now a successful treatment option for both pediatric and adult patients with a variety of hematologic diseases, and transplant outcomes continue to improve with better HLA matching, UCB unit selection, refinement of conditioning regimens, and expanded supportive and infection prevention regimens.

UMBILICAL CORD BLOOD BANKING

An estimated 700,000 umbilical cord blood (UCB) units have been donated for public use. Given the association between cell dose and engraftment, many centers are choosing larger units (based on total nucleated cell count or CD34+ dose) for transplantation, even for pediatric patients [1, 2]. There are currently more than 100 UCB banks collecting units for public use in North America, South America, Australia, Europe, Asia, and the Middle East. In the United States, federal regulations require that a UCB must either be licensed by the Food and Drug Administration (FDA) or used under an Investigational New Drug (IND) protocol.

Private or family UCB banks collect units for family use; an estimated 4 million units have been stored for private use [3]. In Europe, hybrid UCB banking is an innovative strategy to use private donations to fund the public banking side, and families can opt to have privately stored UCB units available for patients in need [4].

Major Challenges in Umbilical Cord Blood Banking

1. Regulatory issues, such as licensure, have increased the cost to bank UCB units.
2. Less than 1 in 10 stored UCB units are used for transplantation, also increasing the costs [5].
3. Some obstetrical practices, such as delayed cord clamping, may affect the volume and cell dose collected [6].

Future Directions in Umbilical Cord Blood Banking

Umbilical cord blood banks have adapted to economic challenges by carefully selecting units to human leukocyte antigen (HLA) type, freeze, and store. Many banks have increased their minimum cell dose to 125 or 150 × 10^7 nucleated cells before processing UCB units [5]. In addition, the use of automated freezing practices is more widespread [7]. Innovative ways to use public and private funds to support UCB initiatives are under way. Newer ways to thaw UCB cells at the transplant center, using a dilution and no-wash method, may increase cell recovery [8, 9].

CORD BLOOD TRANSPLANT FOR HEMATOLOGIC DISEASES

Umbilical cord blood transplant (UCBT) is potentially curative therapy for patients with leukemia,
lymphoma, myeloma, myeloproliferative disorders, genetic diseases, and disorders of metabolism. UCB is particularly important for patients of non-Western European ancestry, because these patients have a difficult time finding a matched volunteer donor in the donor registry [10]. The use of double cord blood transplant and reduced intensity regimens in adults has led to increased use in older patients and reduced transplant-related mortality [11, 12].

**Major Challenges in Cord Blood Transplant for Hematologic Diseases**

1. Engraftment and immune reconstitution are delayed, which leads to an increased risk of infection [13].

2. The cost of acquisition of two cord blood grafts (for double cord blood transplant in adults) can be $80,000, in addition to the cost of the transplant admission and immediate post-transplant care [14].

3. Relapse of the primary disease remains the major cause of death for patients post-transplant.

**Future Trends in Cord Blood Transplant for Hematologic Diseases**

There are many techniques under investigation to improve immune reconstitution and engraftment (Table 1). Expansion trials include efforts with mesenchymal progenitor cell expansion, which showed a neutrophil engraftment of 15 days, improved from a historical control of 24 days [15]. Using the notch ligand Delta 1, Delaney and colleagues improved neutrophil engraftment to 16 days [16]. This work has now been extended to use an “off-the-shelf” non-HLA-matched expanded UCB product, and a phase II study is under way (NCT01690520). The use of copper chelation led to the development of the Nicord product, which showed a one-year overall survival of 82% and 11 days to neutrophil engraftment in a phase I study [17]. The product recently obtained breakthrough designation from the FDA, and a phase III registration trial comparing expanded versus unexpanded UCB is in progress (NCT02730299). While expansion studies are promising, the studies have been limited by small sample size and complex technology that may be difficult to export to other centers.

Another approach is to improve homing of the infused UCB cells to the bone marrow. The Boston group has used prostaglandin E2 to upregulate CXCR4 expression and has shown improved engraftment [11]. Other strategies include the use of fucosylation, hyperbaric oxygen, and direct intramarrow injection of the UCB cells [18–21]. Additional efforts to reduce infection include the use of cytotoxic T lymphocytes to decrease viral infection [22].

If expansion and homing techniques prove successful, this work may decrease the cost of cord blood transplant by eliminating the need for the second UCB unit. Single unit UCBT has been shown to be equivalent to double UCBT in children and may also be acceptable in younger adults [4, 23].

Although relapse remains the major cause of death, recent work from the Seattle group has shown that for patients with minimal residual disease, UCBT is associated with a lower risk of relapse than for patients receiving unrelated donor transplants [24]. In addition, for transplant in general, targeted post-transplant maintenance therapy, such as for patients with FLT3-positive acute myeloid leukemia, may decrease the risk of relapse [25, 26].

**Cord Blood Transplantation in Regenerative Medicine**

An exciting new development is the use of either autologous or unrelated UCBT for nontraditional applications (outside of oncology) in neurology, endocrinology, and cardiology, for diseases that have significant worldwide impact. Compared with stem cells obtained from adult bone marrow harvests, UCB stem cells have greater proliferative potential and longer telomeres [27]. UCB has been used to treat neurologic conditions, including cerebral palsy, hypoxic ischemic encephalopathy, traumatic brain injury, and autism [28]. In cardiovascular disease, UCB-derived mesenchymal stem cells are in clinical trials for dilated cardiomyopathy and ischemic disease [29].

**Major Challenges in Cord Blood Transplantation in Regenerative Medicine**

1. Trial endpoints may be more difficult to quantitate than in hematologic malignancies, for example improved function in cerebral palsy [30].

2. There are significant regulatory hurdles for large-scale use of these products.

3. Use of autologous UCB units for regenerative medicine indications may affect UCB public banking.

**Future Trends in Cord Blood Transplantation in Regenerative Medicine**

This is a fast-moving field with several clinical trials under way. In cerebral palsy, intravenous autologous UCB infusions have been administered safely [30]. Neurodevelopmental improvement has been seen in a study of 57 patients treated with G-CSF with or without autologous peripheral blood stem cells [31]. Allogeneic infusions have also been used; 47 patients with severe cerebral palsy were treated safely with unmatched allogeneic UCB cells, given both intravenously and intrathecally [32]. Gross motor function scores improved, and there was no graft-versus-host disease [33].

Approximately 15 million babies are born preterm worldwide, and these babies are at much higher risk of neurodevelopmental abnormalities, likely related to hypoxia-ischemia [34]. Rat models

---

### Table 1. Strategies to improve engraftment and immune recovery

| Agent                        | Mechanism                      | Author              | n  | Days to ANC > 500 | Current trial       |
|------------------------------|--------------------------------|---------------------|----|-------------------|---------------------|
| Nicotinamide                 | Inhibit enzymes that require NAD+| Horwitz et al. [17] | 11 | 13                | NCT01730099         |
| Notch                        | Inhibit differentiation        | Delaney et al. [16] | 10 | 16                | NCT01690520         |
| Mesenchymal stem cells       | Improve stroma                 | De Lima et al. [15] | 31 | 15                | NCT01854567         |
| Prostaglandin E2             | Homing                         | Cutler et al. [11]  | 12 | 17                |                     |
| FT-VI                        | Fucosylation                   | Popat et al. [18]  | 7  | 14                | NCT01471067         |
| Sitagliptin                  | DPP-IV inhibition              | Farag et al. [45]  | 24 | 21                | NCT01720264         |
| Intrabone marrow             | Homing                         | Kurtta et al. [21] | 15 | 17                |                     |

Abbreviations: ANC, absolute neutrophil count; FT, fucosyltransferase; DPP, dipeptidyl peptidase; NAD+, nicotinamide adenine dinucleotide.
have shown an improvement in motor function after transplantation of human cord blood [35]. Clinical trials using UCB are ongoing at Duke and National University Hospital, Singapore (NCT00593242) [28, 36].

In cardiovascular disease, UCB mesenchymal stem cells secrete cytokines that stimulate angiogenesis [37]. In rat models of myocardial infarction, UCB-derived mesenchymal stem cells have been shown to decrease infarct size, improve cardiac function, and promote angiogenesis via activating platelet-derived growth factor D [38, 39].

Human UCB-derived cells are also being studied to treat inflammatory bowel disease, corneal disease, renal disease, and collagen-induced arthritis [40–42]. A clinical trial in 45 patients with hepatitis B-induced liver disease has shown a benefit to UCB-derived mesenchymal stem cells [43]. A partial listing of available clinical trials for UCB-derived cells for regenerative medicine applications is shown in Table 2.

### Table 2. Selected active and recruiting regenerative medicine human cord blood trials

| Disease                          | Agent                        | Investigator | Ages (years) | Current trial          |
|----------------------------------|------------------------------|--------------|--------------|------------------------|
| Autism                           | Auto or Allo UCB             | Kurtzberg    | 2–7          | NCT02547183            |
| Cerebral palsy                   | Auto UCB                    | Carroll      | 1–12         | NCT01072370            |
| Cerebral palsy                   | Auto UCB                    | Lee          | 2–10         | NCT02866331            |
| Ischemic stroke                  | Allo UCB                    | Kurtzberg    | 18–90        | NCT03004976            |
| Chronic ischemic cardiomyopathy  | UCB-derived mesenchymal stem cells | Dai       | 35–65        | NCT02635464            |
| Crohn’s disease                  | UCB-derived stem cells       | Lee          | 20–70        | NCT02000362            |

Abbreviations: G-CSF, granulocyte colony-stimulating factor; UCB, umbilical cord blood;

**CONCLUSION**

From the first UCBT in 1988, the field of UCBT has evolved considerably [44]. UCBT is now a successful treatment option for both pediatric and adult patients with a variety of hematologic diseases, and transplant outcomes continue to improve with better HLA matching, UCB unit selection, refinement of conditioning regimens, and expanded supportive and infection prevention regimens. Exciting new applications in the field of cardiology, neurology, autoimmunity disease, and ophthalmology should make major health advances in the next 10 years.

**REFERENCES**

1. Barker JN, Byam CE, Scaradavou A et al. Availability of cord blood extends allogeneic hematopoietic transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 2010;11:1541–1548.
2. Purtilo D, Smith KM, Tonomi J et al. Analysis of 402 cord blood units to assess factors influencing infused viable CD34+ cell dose: The critical determinant of engraftment. Blood 2013;122:296–300.
3. Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation: Public or private? Bone Marrow Transplant 2015;50:1271–1278.
4. Wagner JE, Epen M, Carter S et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med 2014;371:1685–1694.
5. Saccardi R, Tucundeva L, Ruggeri A et al. Impact of cord blood banking technologies on clinical outcome: A Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and Net Cord retrospective analysis. Transfusion 2016;56:2021–2029.
6. Allen DS, Scrivens N, Lawless T et al. Delayed clamping of the umbilical cord after delivery has implications for public cord blood banking. Transfusion 2016;56:662–665.
7. Nikiforou S, Si L, Snow K et al. Lack of impact of cord blood processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy 2017;19:272–2828.
8. Akel S, Regan D, Wall D et al. Current thawing and infusion practice of cryopreserved cord blood: The impact on graft quality, recipient safety, and transplantation outcomes. Transfusion 2014;54:2997–3009.
9. Dahlg P8, Ponce DM, Devlin S et al. “No wash” albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment. Biol Blood Marrow Transplant 2014;20:490–494.
10. Barker JN, Byam C, Scaradavou A. How I treat: The selection and acquisition of unrelated cord blood grafts. Blood 2011;117:2332–2339.
11. Cutler C, Multani P, Robbins D et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013;122:3074–3081.
12. Barker JN, Weisdorf DJ, DeFor TE et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced intensity conditioning. Blood 2003;102:1915–1919.
13. Brunstein CG, Gutman JA, Weisdorf DJ et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: Relative risks and benefits of double umbilical cord blood. Blood 2010;116:4603–4609.
14. Ballen KK, Joffe S, Brazaukas R et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: Comparison among alternative graft sources. Biol Blood Marrow Transplant 2014;20:1819–1827.
15. de Lima M, McNiece I, Robinson SN et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012;367:2305–2315.
16. Delaney C, Heimfeld S, Brashem-Stein C et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010;16:232–236.
17. Horwitz ME, Chao NJ, Rizieri DA et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 2014;124:3121–3128.
18. Popat UR, Oran B, Hosing CM et al. Ex vivo fucosylation of cord blood accelerates neutrophil and platelet engraftment. Blood 2013;122:691–695.
19. Thompson PA, Rezvani K, Hosing CM et al. Umbilical cord blood graft engineering: Challenges and opportunities. Bone Marrow Transplant 2015;50(suppl 2):S55–S62.
20. Frassoni F, Gualandi F, Podesta M et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukemia: A phase I/II study. Lancet Oncol 2008;9:831–839.
21. Kurita N, Gosho M, Yokoyama Y et al. A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematologic recovery with the Japanese nationwide database. Bone Marrow Transplant 2017 [Epub ahead of print].
22. Gerdemann U, Katarri UL, Papadopoulos A et al. Safety and clinical efficacy of rapidly-generated virus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013;21:2113–2121.
23. Michel G, Galambrun C, Sirvent A et al. Single-vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. Blood 2016;127:3450–3457.
24. Milano F, Gooley T, Wood B et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med 2016;375:944–953.
25. Chen YB, Li S, Lane AA et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic cell transplantation for fms-like...
tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014;20:2042–2048.

26 Brunner AM, Li S, Fathi AT et al. Hematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukemia in first complete remission. Br J Hematol 2016;175:496–504.

27 van de Ven C, Collins D, Bradley MB et al. The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. Exp Hematol 2007;35:1753–1765.

28 Cotten CM, Murtha AP, Goldberg RN et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr 2014;164:973–979.

29 Wu KH, Zhou B, Mo XM et al. Therapeutic potential of human umbilical cord-derived stem cells in ischemic diseases. Transplant Proc 2007;39:1620–1622.

30 Sun J, Allison J, McLaughlin C et al. Differences in quality between privately and publicly banked umbilical cord blood infusion units: A pilot study of autologous cord blood cells in children with acquired neurologic disorders. Transfusion 2010;50):1980–1987.

31 Rah WJ, Lee YH, Moon JH et al. Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: A randomized, double-blind, cross-over study. J Transl Med 2017;15:16.

32 Feng M, Lu A, Gao H et al. Safety of allogeneic umbilical cord blood stem cells therapy in patients with severe cerebral palsy: A retrospective study. Stem Cells International dx.doi.org/10.1155/2015/325652

33 Feng M, Gao HX, Dai P et al. Clinical observation on the efficacy of umbilical blood stem cell transplantation in 30 cases with severe cerebral palsy. Chinese Journal of Blood Transfusion 24.7 (2011): 602–604.

34 Blencowe H, Cousens S, Oestergaard MZ et al. National, regional, and worldwide estimates of perinatal birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. Lancet 2012;379:2162–2172.

35 Wasielewski B, Jenssen A, Roth-Häger A et al. Neuroglial activation and Cx43 expression are reduced upon transplantation of human umbilical cord blood cells after perinatal hypoxic-ischemic injury. Brain Res 2012;1487:39–53.

36 Li J, McDonald CA, Fahey MC et al. Could cord blood cell therapy reduce perinatal brain injury? Front Neurol 10:3389/fneur.2014.00200.

37 Medhekar SK, Shende VS, Chincholkar AB. Recent stem cell advances: Cord blood and induced pluripotent stem cell for cardiac regeneration: A review. Int J Stem Cells 2016;9:21–30.

38 Ma J, Zhao Y, Sun L et al. Exosomes derived from Akt-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D. Stem Cells Transl Med 2017;6:51–59.

39 Furfaro EM, Gabella MA. Do adult stem cells ameliorate the damaged myocardium? Human cord blood as a potential source of stem cells. Curr Vasc Pharmacol 2007;5:27–44.

40 Mao F, Wu Y, Tang Z et al. Human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease through the regulation of 15-LOX-1 in macrophages. Biotechnol Lett 2017 [Epub ahead of print].

41 Shao C, Chen J, Chen P et al. Targeted transplantation of human umbilical cord blood endothelium progenitor cells with immunomagnetic nanoparticles to repair corneal endothelium defect. Stem Cell Dev 2015;24:756–767.

42 Peng X, Xu H, Zhou Y et al. Human umbilical cord mesenchymal stem cells attenuate cisplatin-induced acute and chronic renal injury. Exp Biol Med (Maywood) 2013;238:960–970.

43 Li YH, Xu Y, Wu HM et al. Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus related acute-on-chronic liver failure treated with plasma exchange and entecavir: A 24-month prospective study. Stem Cell Rev 2016;12:645–653.

44 Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: The first 25 years and beyond. Blood 2013;122:491–498.

45 Farag SS, Srivastava S, Messina-Graham S et al. In-vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematologic malignancies. Stem Cells Dev 2013;22:1007–1015.